manidipine

ApprovedSmall molecule

UUniversity of Erlangen-Nürnberg Medical School

manidipine is one of 53 small molecule programs targeting Calcification. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CalcificationActive, not recruiting

HypertensionActive, not recruiting

CalcificationPhase 2

Active, not recruiting

HypertensionApproved

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

manidipine

UUniversity of Erlangen-Nürnberg Medical School

Approved

1 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Apresoline

Novartis

Preclinical

7 5

Zebeta

Teva

Preclinical

6 6

Edarbi

Takeda

Preclinical

4 7

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 8

Alphagan

AbbVie

Preclinical

—9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 10

Disalcid

JJoslin Diabetes Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Calcification

NCT07091136

Clinical

Trials by Indication[1]

Calcification1 trial

Exploration of Manidipine to Reverse Aortic Valve Calcification

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07091136·100 enrolled

Hypertensive1 trial

A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT00627952·100 enrolled

Hypertension1 trial

Manidipine Versus Amlodipine in Patients With Hypertension

Terminated·KKorea University Guro Hospital·Phase 4·NCT03106597·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for manidipine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — manidipine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for manidipine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Erlangen-Nürnberg Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Erlangen-Nürnberg Medical School

manidipine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Calcification1 trial

Hypertensive1 trial

Hypertension1 trial

References

Drug Info

Quick Facts

Related News